» Articles » PMID: 30483412

Estimating Health Opportunity Costs in Low-income and Middle-income Countries: a Novel Approach and Evidence from Cross-country Data

Overview
Journal BMJ Glob Health
Specialty Public Health
Date 2018 Nov 29
PMID 30483412
Citations 136
Authors
Affiliations
Soon will be listed here.
Abstract

The economic evaluation of healthcare interventions requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the additional resources required had, instead, been made available for other healthcare activities. Therefore, some assessment of these health opportunity costs is required if the best use is to be made of the resources available for healthcare. This paper provides a framework for generating country-specific estimates of cost per disability-adjusted life year (DALY) averted 'thresholds' that reflect health opportunity costs. We apply estimated elasticities on mortality, survival, morbidity and a generic measure of health, DALYs, that take account of measures of a country's infrastructure and changes in donor funding to country-specific data on health expenditure, epidemiology and demographics to determine the likely DALYs averted from a 1% change in expenditure on health. The resulting range of cost per DALY averted 'threshold' estimates for each country that represent likely health opportunity costs tend to fall below the range previously suggested by WHO of 1-3× gross domestic product (GDP) per capita. The 1-3× GDP range and many other previous and existing recommendations about which interventions are cost-effective are not based on an empirical assessment of the likely health opportunity costs, and as a consequence, the health effects of changes in health expenditure have tended to be underestimated, and there is a risk that interventions regarded as cost-effective reduce rather than improve health outcomes overall.

Citing Articles

Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.

Gao M, Hu S, Zhao X, You T, Hong Y, Liu Y Lancet Reg Health West Pac. 2025; 56:101499.

PMID: 40061912 PMC: 11889945. DOI: 10.1016/j.lanwpc.2025.101499.


Estimating the potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study.

Clark R, Portnoy A, Weerasuriya C, Sumner T, Bakker R, Harris R Lancet Reg Health Southeast Asia. 2025; 31:100424.

PMID: 39957772 PMC: 11827003. DOI: 10.1016/j.lansea.2024.100424.


Quantifying the potential value of entomological data collection for programmatic decision-making on malaria control in sub-Saharan African settings.

Schmit N, Topazian H, Pianella M, Charles G, Winskill P, Hancock P Malar J. 2025; 24(1):31.

PMID: 39885514 PMC: 11780794. DOI: 10.1186/s12936-025-05251-7.


Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: An individual-based modeling study.

Hickey M, Ayieko J, Kabami J, Owaraganise A, Kakande E, Ogachi S PLoS Med. 2025; 22(1):e1004531.

PMID: 39854581 PMC: 11805449. DOI: 10.1371/journal.pmed.1004531.


Estimating the epidemiological and economic impact of providing nutritional care for tuberculosis-affected households across India: a modelling study.

McQuaid C, Clark R, White R, Bakker R, Alexander P, Henry R Lancet Glob Health. 2025; 13(3):e488-e496.

PMID: 39824201 PMC: 11865009. DOI: 10.1016/S2214-109X(24)00505-9.


References
1.
Vallejo-Torres L, Garcia-Lorenzo B, Castilla I, Valcarcel-Nazco C, Garcia-Perez L, Linertova R . On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?. Value Health. 2016; 19(5):558-66. DOI: 10.1016/j.jval.2016.02.020. View

2.
Edney L, Haji Ali Afzali H, Cheng T, Karnon J . Mortality reductions from marginal increases in public spending on health. Health Policy. 2018; 122(8):892-899. DOI: 10.1016/j.healthpol.2018.04.011. View

3.
Filmer D, Pritchett L . The impact of public spending on health: does money matter?. Soc Sci Med. 1999; 49(10):1309-23. DOI: 10.1016/s0277-9536(99)00150-1. View

4.
Culyer A . Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. Health Econ Policy Law. 2016; 11(4):415-32. DOI: 10.1017/S1744133116000049. View

5.
Woods B, Revill P, Sculpher M, Claxton K . Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016; 19(8):929-935. PMC: 5193154. DOI: 10.1016/j.jval.2016.02.017. View